SCHEMBL2415029

SCHEMBL2415029

OB(O)Oc1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 15/20 0.45
FFAR1 O14842 2/20 0.45
PDE2A O00408 1/20 0.45
MEN1 O00255 1/20 0.41
TTR P02766 1/20 0.41
PPOX P50336 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27705367 0.86 PDE2A (0.41) MRGPRX4PDE2AMEN1KMT2A
SCHEMBL31351020 0.80 PDE2A (0.42) MRGPRX4PDE2AKMT2A
SCHEMBL28024774 0.80 MRGPRX4 (0.43) MRGPRX4FFAR1
SCHEMBL31053746 0.80 CES2 (0.46)
SCHEMBL7590939 0.80 CES2 (0.46)
SCHEMBL30705412 0.80 MGLL (0.39) MEN1KMT2A
SCHEMBL2412562 0.80 PDE2A (0.42) MRGPRX4PDE2AKMT2A
SCHEMBL10936074 0.79 MRGPRX4 (0.48) MRGPRX4FFAR1PDE2A
SCHEMBL10707742 0.79 FFAR1 (0.54) MRGPRX4FFAR1PDE2AMEN1TTR
SCHEMBL28549368 0.78 CES2 (0.47) PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106470972-A Sulfonylaminobenzamide compounds 瑞士诺华动物保健有限公司 2017-03-01 CN disclosed
CN-102665415-A Mixtures of mesoionic pesticides DU PONT 2012-09-12 CN disclosed
CN-102574788-A Indole derivatives as crac modulators HOFFMANN LA ROCHE 2012-07-11 CN disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
CN-1993120-B Arylacetic acids and related compounds for treatment of alzheimer's disease MERCK SHARP & DOHME BLURTON PETER 2010-05-05 CN disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
CN-1993120-A Arylacetic acids and related compounds for treatment of alzheimer's disease MERCK SHARP & DOHME BLURTON PE (GB) 2007-07-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG MRGPRX4 1764/4885FFAR1 15/4885PDE2A 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.